About Us

Omnio AB is a biotechnical research and development company located in Umeå, northern Sweden founded in 2001 by Professor Tor Ny.

Omnio’s focus is to develop biological drug candidates based on the plasma-derived protease plasminogen.  Fundamental for the development is pre-clinical research studies conducted in collaboration with Umeå University.

Management

Patric Stafshede, CEO

Mr. Stafshede has an MSc degree in Chem Eng from Chalmers University of Technology in Gothenburg, Sweden, and an MBA degree from AB Freeman School of Business at Tulane University, New Orleans, USA. He has previous international experience from McKinsey & Co, Alfa Laval Agri, and Entergy Corp in both Russia and the US.

Tor Ny, PhD, Professor, Founder, Vice President, R&D

Tor Ny is a professor of Medical Biochemistry at Umeå University, Sweden. His primary research focus is the role of plasminogen as a key regulator of physiological inflammation, including wound healing. Professor Ny has conducted research on plasminogen activation extracellular proteolysis for about 30 years.

In addition to his academic endeavours, Professor Ny has founded Umeå Biotech Incubator, a biotech incubator where young start-ups can get coaching, pre-seed funding and access to laboratories. He has also founded or co-founded other biotech companies.  Click here to read more…

Patric foto small
Professor Ny

Malgorzata Wilczynska, PhD,CSO

Dr. Wilczynska has a PhD in Medical Biochemistry and Biophysics and extensive experience on the biochemistry of plasminogen and the plasminogen activator system including studies with animal models of wound healing. She has been working at Omnio since 2007.

CSO Wilczynska

Scientific Advisors

Sten Hellström, MD, PhD, Professor

Sten Hellström is senior professor of Ear, Nose and Throat at the Karolinska Institute and the Karolinska University Hospital in Stockholm, Sweden. Professor Hellström is a leading authority in middle ear research and in particular research concerning tympanic membrane and healing of tympanic membrane perforations. Click here to read more…

Ola Camber, PhD, Assistant Professor

Ola Camber is an expert in drug development and regulatory affairs. He has many years of experience from Big Pharma as well as from smaller biotech companies.

Hans Boström, PhD

Hans Boström is a specialist in clinical research. He has many years of previous experience with Merck, Sharp & Dohme and AstraZeneca.

Board of Directors

Lars Johansson, Chairman of the Board,
Mr. Johansson is an experienced industrialist, previously invstment adviser to the Swedish Government’s pension fund. He is currently Director or Chairman of several company boards, most notably he serves as Chairman of O.F. Ahlmarks, with more then € 300 million in revenues.

Henrik Bergdahl,
Mr. Bergdahl’s academic background is in economics and law, and he has a long experience of entrepreneurial companies in the life science sector. He has served as the CFO of Umeå Biotech Incubator, and is currently chairman of the board of CMTF Affärsutveckling AB.

Tor Ny, Professor, Founder,
See management section above.